Latest news with #Aptar
Business Wire
a day ago
- Business
- Business Wire
Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod ® nasal spray pump - one of the delivery systems for Haleon's Otrivin ® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. Aptar Pharma announces that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally Share Reinforcing circularity in pharmaceutical packaging Aptar Pharma's Freepod ® spray pump used with Haleon's Otrivin ® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device. ISCC PLUS certified manufacturing and supply chain Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod ® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod ® components. Partnership for a more sustainable approach The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin ® Freepod ® winning the World Packaging Award in 2019 for its innovative and sustainable design. The use of bio-based or renewable feedstocks for the Otrivin ® products with Freepod ® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma's Freepod ® for Otrivin ®, available globally, demonstrates Aptar's commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon's latest microdroplet technology, which is being rolled out globally since 2023. 'At Aptar, sustainability is not just a responsibility - it's a strategic advantage,' commented Gael Touya, President of Aptar Pharma. 'The launch of Freepod ® Futurity™ reflects our commitment to developing solutions that respond to consumers' increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin ® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient.' With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals. *ISCC Plus certified bio-based feedstock, mass balance approach. **The end point for the goal delivery period is the end of the 2025 calendar year. About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
Business Wire
15-07-2025
- Business
- Business Wire
Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announces its acquisition of the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. This strategic move strengthens Aptar's support for early-stage drug development by offering formulation, fill and finish services for Phase 1 and 2 clinical trials and enhances adoption of its proprietary devices in early-stage clinical programs. This acquisition builds on a successful collaboration between Aptar Pharma and Mod3 Pharma, particularly in serving Aptar Pharma customers with Phase 1 and Phase 2 cGMP fill and finish services for orally inhaled nasal drug products (OINDPs), filling a largely unmet need in the market. The capabilities acquired also help Aptar address a growing market demand for agile, high-quality Current Good Manufacturing Practices (cGMP) clinical trial material supply services that complement the segment's existing service offerings. Additionally, the acquisition accelerates the adoption of new drug delivery technologies, initially focusing on OINDPs, with potential expansion into dermal, ophthalmic, injectable and secondary packaging solutions using Aptar's Active Material Science Solutions. Aptar Pharma will now operate an FDA-inspected, state-of-the-art facility in Boonton, New Jersey. The site includes cGMP cleanrooms, high-potency Active Pharmaceutical Ingredient (API) suites, biologics capabilities, and advanced fill-finish technologies - fully aligned with Aptar Pharma's drug delivery solutions portfolio. Gael Touya, President of Aptar Pharma, commented, 'Our vision at Aptar Pharma is clear: From formulation to patient. By integrating Phase 1 and 2 clinical manufacturing capabilities, we're not just expanding our technical footprint - we're deepening our commitment to customers seeking a seamless and accelerated path to market. This move reinforces our position as a trusted partner from molecule to delivery, and ultimately, to the patient.' Sai Shankar, President, M&A, Strategy, Business Development, Marketing, Drug Services, added, 'We're expanding our niche services to help customers move faster in areas of unmet need, and without duplicating the strengths of our trusted partners. This strategic expansion of our services builds on our legacy in drug dosing and dispensing systems by integrating deeper expertise as a drug delivery innovator, as well as product development and formulation, allowing us to offer more specialized and holistic support to our customers.' Dr. Paul Shields, CEO of Mod3 Pharma, remarked, 'We are delighted to become part of the Aptar family. This acquisition reflects our shared commitment of accelerating the development of innovative therapies and bringing them to patients faster.' About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit
Business Insider
09-07-2025
- Business
- Business Insider
AptarGroup debuts dual-active technology to control moisture, oxygen
AptarGroup (ATR) announced it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. The company stated this technology is designed to provide a singular solution to address degradation drivers for pharmaceutical drugs, including oral solid dose GLP-1 medications, and medical devices. The new solution marks a breakthrough in the pharmaceutical industry and extends Aptar's 3-Phase Activ-Polymer technology into new use cases. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Wire
08-07-2025
- Business
- Business Wire
Aptar's Dual-Active Material Science Technology Simultaneously Controls Moisture and Oxygen for Pharmaceutical Drugs and Medical Devices
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution to address these degradation drivers for pharmaceutical drugs, including oral solid dose glucagon-like peptide-1 (GLP-1), medical devices and more. This new solution marks a significant material science breakthrough in the pharmaceutical industry, extending Aptar CSP Technologies' 3-Phase Activ-Polymer™ technology into new use cases where a combination of humidity and oxidation can compromise the efficacy, safety, and shelf life of sensitive oral solid dose drugs, medical devices, implantable mesh devices, microarray patches and transdermal delivery systems. 'This launch reflects years of development, engineering excellence, and a deep understanding of our customers' most pressing stability challenges,' said Badre Hammond, Vice President Commercial Operations and General Manager, Aptar CSP Technologies. 'There has never been a singular, standalone active material aimed at protecting against both oxidation and moisture-related degradation at this level of precision across multiple platforms. We're proud to offer a solution that is not only scientifically differentiated but can also be commercially validated.' Aptar's new dual-active technology can be customized for a range of product formats and development stages, from early R&D to commercial launch. Aptar's technology can help support regulatory compliance and product protection across a variety of formats, aimed at helping companies meet strict International Council for Harmonization (ICH) stability requirements while maintaining performance and integrity of sensitive drug or device components. In addition to protection technology for oral solid dose GLP-1, Aptar also offers a range of high-quality elastomeric components for GLP-1 drug products, including plungers and rigid needle shields. Pharmaceutical companies have validated Aptar's elastomeric components and are partnering with Aptar to develop injectable solutions for GLP-1. By combining digital and Aptar's patient services, Aptar offers fully integrated solutions, which helps drug manufacturers create differentiated drug delivery systems and enhance patient experiences for GLP-1 and other applications. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Aptar CSP Technologies leverages its active material science expertise to transform ideas into market opportunities, accelerate and de-risk the product development process, and provide complete solutions that improve consumers' and patients' lives. The company offers a complete set of services from concept ideation, to design and engineering, to product development, global production, quality control, and regulatory support that results in expedited speed-to-market. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit and This press release contains forward-looking statements, including the potential outcomes of the 3-Phase Activ-Polymer™ technology. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as 'expects,' 'anticipates,' 'believes,' 'estimates,' 'future,' 'potential,' 'continues' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.
Business Wire
25-06-2025
- Business
- Business Wire
Aptar Named One of the World's Most Sustainable Companies by TIME for Second Consecutive Year
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of the World's Most Sustainable Companies 2025 by TIME. Aptar is ranked 244 out of 500 global companies evaluated by TIME and its partner Statista. This recognition highlights our commitment to furthering a more sustainable future through increasing renewable energy use, creating more recyclable and reusable products and helping the world's leading brands meet their sustainability commitments. Share 'We are proud to be named one of TIME's World's Most Sustainable Companies for the second year in a row,' said Stephan B. Tanda, Aptar President and CEO. 'This recognition highlights our commitment to furthering a more sustainable future through increasing renewable energy use, creating more recyclable and reusable products and helping the world's leading brands meet their sustainability commitments. Our global sustainability strategy helps to ensure that we attract and retain world class talent, prioritize responsible and forward-thinking actions and enhances our competitive positioning by leading with best practices and driving more sustainable innovations.' The World's Most Sustainable Companies 2025 ranking recognizes leading companies in corporate social responsibility from around the globe. Companies were evaluated in more than 20 key performance indicators related to sustainability, such as compliance with international reporting standards, emissions, or commitment to goals and initiatives. Based on this multi-layered analysis, a score was determined for each company. Out of over 5,000 of the world's largest and most influential companies assessed, the top 500 were awarded based on revenue, market capitalization and public prominence. As outlined in the Company's 2024 Corporate Sustainability Report, Aptar has made considerable progress advancing key areas of its global sustainability strategy. Aptar achieved the Platinum level rating in recognition of its sustainability efforts from EcoVadis for the fifth consecutive year, placing the Company among the top 1% of the more than 150,000 companies rated by EcoVadis across all industries. In recognition of the Company's actions to cut emissions, mitigate climate risks and further the low-carbon economy, Aptar was named to the global environmental non-profit CDP 'A List'. At year-end 2024, 97.5% of Aptar's global electricity was from renewable sources. As a complement, Aptar entered into renewable supply agreements in Europe and North America to reinforce its commitment to sustainability and reducing greenhouse gas (GHG) emissions and provide a more localized source of renewable energy dedicated to the Company. In addition, 86% of operational waste avoided disposal to landfill through reuse, recycling and recovery and over 60% of Aptar's sites have earned Landfill Free Certification through Aptar's internal program. Aptar also partners with the Ellen MacArthur Foundation, the World Business Council for Sustainable Development, and others, and it continues to focus on circularity by increasing recycled resin content and aiming towards 100% recyclable, reusable, or compostable solutions across personal care, beauty, home care and food and beverage. The Company is also working towards more responsible products through collaboration with suppliers and partners. For a full list of the World's Most Sustainable Companies 2025 and a breakdown of the methodology, please visit the TIME website. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit This press release contains forward-looking statements, such as statements regarding our sustainability targets, including our climate and other environmental-related commitments and renewable energy targets and operational strategies. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as 'expects,' 'anticipates,' 'believes,' 'estimates,' 'future,' 'potential,' 'continues' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. There is no guarantee that these 'forward-looking statements' will happen due to a number of factors, including assumptions not being realized, scientific or technological developments, evolving sustainability strategies, evolving legal and regulatory requirements, our expansion into new geographic regions, and potentially, those set forth in the 'Risk Factors' section of our most recent Annual Report on Form 10-K and subsequent filings. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.
